Autologous transplant vs oral chemotherapy and lenalidomide in newly diagnosed young myeloma patients: a pooled analysis
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61988987%3A17110%2F17%3AA1801RYM" target="_blank" >RIV/61988987:17110/17:A1801RYM - isvavai.cz</a>
Alternative codes found
RIV/00843989:_____/17:E0106575
Result on the web
<a href="http://dx.doi.org/10.1038/leu.2016.381" target="_blank" >http://dx.doi.org/10.1038/leu.2016.381</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1038/leu.2016.381" target="_blank" >10.1038/leu.2016.381</a>
Alternative languages
Result language
angličtina
Original language name
Autologous transplant vs oral chemotherapy and lenalidomide in newly diagnosed young myeloma patients: a pooled analysis
Original language description
In newly diagnosed myeloma patients, upfront autologous transplant (ASCT) prolongs progression-free survival 1 (PFS1) compared with chemotherapy plus lenalidomide (CC+R). Salvage ASCT at first relapse may still effectively rescue patients who did not receive upfront ASCT. To evaluate the long-term benefit of upfront ASCT vs CC+R and the impact of salvage ASCT in patients who received upfront CC+R, we conducted a pooled analysis of 2 phase III trials (RV-MM-209 and EMN-441). Primary endpoints were PFS1, progression-free survival 2 (PFS2), overall survival (OS). A total of 268 patients were randomized to 2 courses of melphalan 200 mg/m(2) and ASCT (MEL200-ASCT) and 261 to CC+R. Median follow-up was 46 months. MEL200-ASCT significantly improved PFS1 (median: 42 vs 24 months, HR 0.53; P < 0.001), PFS2 (4 years: 71 vs 54%, HR 0.53, P < 0.001) and OS (4 years: 84 vs 70%, HR 0.51, P < 0.001) compared with CC+R. The advantage was noticed in good and bad prognosis patients. Only 53% of patients relapsing from CC+R received ASCT at first relapse. Upfront ASCT significantly reduced the risk of death (HR 0.51; P = 0.007) in comparison with salvage ASCT. In conclusion, these data confirm the role of upfront ASCT as the standard approach for all young myeloma patients.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30205 - Hematology
Result continuities
Project
—
Continuities
V - Vyzkumna aktivita podporovana z jinych verejnych zdroju
Others
Publication year
2017
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
LEUKEMIA
ISSN
0887-6924
e-ISSN
1476-5551
Volume of the periodical
31
Issue of the periodical within the volume
8
Country of publishing house
GB - UNITED KINGDOM
Number of pages
8
Pages from-to
1727-1734
UT code for WoS article
000406781900008
EID of the result in the Scopus database
2-s2.0-85010892441